加拿大儿童13价肺炎球菌结合疫苗接种规划实施后2010-2016年65岁及以上成人侵袭性肺炎链球菌血清型分布
研究分析了2010至2016年加拿大65岁及以上成人中7282株侵袭性肺炎链球菌的血清型及2527株的药敏结果。PCV13额外6种血清型占比从39.5%显著降至18.6%,PPV23血清型和非疫苗血清型分别从26.3%和25.1%显著升至36.2%和38.4%,抗菌药物耐药率无显著变化。
要点
- PCV13额外6种血清型占比从2010年39.5%显著降至2016年18.6%
- PPV23血清型和非疫苗血清型占比分别显著升至36.2%和38.4%
- 2011至2016年抗菌药物耐药率无显著变化
核心结论
- 尽管2010至2016年65岁及以上成人侵袭性肺炎球菌病总体发病率保持相对稳定,儿童PCV13疫苗接种规划通过群体免疫效应成功间接减少了成人中由PCV13血清型引起的侵袭性肺炎球菌病。
研究设计与样本
- 研究对2010至2016年加拿大65岁及以上成人中分离的7282株侵袭性肺炎链球菌进行血清分型,并对其中2527株进行抗菌药物敏感性试验;血清分型采用商业抗血清的Quellung反应,药敏采用肉汤微量稀释法。
主要发现
- PCV7血清型占比从2010年9.1%(n=96)非显著降至2016年6.7%(n=72)。
- PCV13额外6种血清型占比从2010年39.5%(n=418)显著降至2016年18.6%(n=201)(p < 0.05)。
- PPV23血清型占比从2010年26.3%(n=278)显著升至2016年36.2%(n=393)(p < 0.05)。
- 非疫苗血清型占比从2010年25.1%(n=266)显著升至2016年38.4%(n=416)(p < 0.05)。
- 2011至2016年抗菌药物耐药率无显著变化:对克拉霉素耐药24.1%(n=609)、多西环素10.0%(n=254)、青霉素11.8%(n=299)、头孢呋辛5.2%(n=131)、克林霉素6.6%(n=168)、甲氧苄啶-磺胺甲噁唑6.0%(n=152)、头孢曲松0.5%(n=12)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 13-valent conjugate vaccine (PCV13) was recommended for childhood immunization programs in 2010 in Canada and has decreased the incidence of invasive pneumococcal disease (IPD) in children and changed the epidemiology of IPD in adults. This study investigated the epidemiology of IPD in adults 65 years of age and older in Canada. A total of 7282 invasive S. pneumoniae isolated from adults ≥65 years old were serotyped from 2010 to 2016 and antimicrobial susceptibility was performed on 2527 isolates. Serotyping was performed by Quellung reaction using commercial antisera and antimicrobial susceptibilities were determined by broth microdilution. PCV7 serotypes decreased non-significantly from 2010 to 2016 from 9.1% (n = 96) to 6.7% (n = 72) while the additional six PCV13 serotypes declined significantly from 39.5% (n = 418) to 18.6% (n = 201) (p < 0.05). The 23-valent pneumococcal polysaccharide vaccine (PPV23) and non-vaccine (NVT) serotypes increased from 26.3% (n = 278) to 36.2% (n = 393) (p < 0.05), and from 25.1% (n = 266) to 38.4% (n = 416) (p < 0.05), respectively. There were no significant changes in antimicrobial resistance rates from 2011 to 2016: 24.1% of the IPD from adults ≥65 years were resistant to clarithromycin (n = 609), 10.0% to doxycycline (n = 254), 11.8% to penicillin (n = 299), 5.2% to cefuroxime (n = 131), 6.6% to clindamycin (n = 168), 6.0% to trimethoprim-sulfamethoxazole (n = 152), and 0.5% (n = 12) to ceftriaxone. Although overall incidence of IPD in adults ≥65 years has remained relatively constant from 2010 to 2016, childhood PCV13 vaccination programs have been successful in indirectly reducing IPD caused by PCV13 serotypes in adults through herd immunity effects.
引用
- Demczuk WHB, Martin I, Desai S, et al. Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016. Vaccine. 2018. PMID: 29937245. doi:10.1016/j.vaccine.2018.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。